Trans-national Access (TA) offers academic and industry researchers from Europe and worldwide the opportunity to remotely access the PDX models, services, and expertise of the EurOPDX Research Infrastructure. As part of the EDIReX grant, three TA calls will be launched between 2018 and 2020.
The 1st TA call opens in October 2018.
Stay tuned for further information and the call announcement at: www.europdx.eu, and on Twitter: @EurOPDX
- Access will be possible through three different “access units”: (i) “Sample” = shipment of frozen PDX tumour samples to selected academic laboratories; (ii) “Deposit” = deposition of PDX models into the repository and infrastructure biobank; (iii) “Test” (as from the 2nd call in 2019) = performance of in vivo preclinical experiments on PDXs engrafted in immunocompromised mice within the 6 nodes
- Cost: Trans-national Access to the EurOPDX Research Infrastructure is free of charge for selected users, costs being covered by the EDIReX grant. However, the shipment cost of the samples must be borne by the applicants.
- Selection procedure: Proposals will be selected by a mixed panel of partners of the EDIReX project (for feasibility under the grant) and an independent committee of external evaluators.
- Full access modalities, including application guidelines, will be displayed upon launching of the 1st TA call in October 2018
Models for access:
Nodes providing access:
TA will be provided by a distributed infrastructure composed of six independent nodes, which are state-of-the-art laboratories or platforms performing research using PDX models:
- University of Torino, Department of Oncology at Candiolo Cancer Institute IRCCS, Xenopatients' Platform for Experimental Oncology (Candiolo, Italy)
- Katholieke Universiteit Leuven, Trace PDX platform (Leuven, Belgium)
- The University of Cambridge, Cancer Research UK Cambridge Institute, Carlos Caldas laboratory (Cambridge, UK)
- Institut Curie, Laboratory of Preclinical Investigation (Paris, France)
- Vall d’Hebron Institute of Oncology, CELLEX building (Barcelona, Spain)
- Netherlands Cancer Institute, Preclinical Intervention Unit of the Mouse Clinic for Cancer and Ageing (Amsterdam, the Netherlands)
application guideline document and application form downloadable here when ready
Proposals will be selected by an external scientific committee according scientific excellence and novelty, study design, and ethical considerations. Access will be organised into units called “Transnational access units, or TAUs”.
The 1st call will offer two types of access to applicants:
Sample-TAU: will include the expansion, biobanking, and delivery to the user of tissue aliquots from one EurOPDX model as vital frozen specimens. The grant will cover; shipment organisation from the delivering partner, sample health check, implant in 2 NSG mice, growth and follow-up, explant and generation of 10 aliquots, quality controls, and archiving. Final shipment will be charged to the user.
Deposit-TAU: will include the expansion and biobanking, by one node, of a PDX model deposited by the user. The grant will cover; shipment organisation from the user, sample receiving and health check, implant in 2 NSG mice, growth follow-up, explant and generation of 10 aliquots, quality controls, and archiving.
…and from 2019
Test-TAU: expansion of in vivo efficacy study of a selected EurOPDX model for response to drugs of choice, and delivery to the user of the test results in the form of a report, including raw data. The grant will cover; transfer of the model to the node, implantation in 2 NSG mice for initial expansion, passage to 10 mice (one arm), growth follow-up, selection and randomisation of 6 mice, treatment and measurement of tumour size for 4-6 weeks, quality controls, data analysis, preparation and delivery of report, with drug response data.